<p>Nkarta, Inc.（納斯達克代碼：NKTX - 免費報告）- 威廉·布萊爾的投資分析師在 11 月 11 日星期二向投資者發佈的研究報告中上調了對 Nkarta 2025 財年每股收益的預期。威廉·布萊爾的分析師 S. Corwin 現在預計該公司 2025 財年每股收益為（$1.36），高於之前預測的（$1.38）。市場普遍預計 Nkarta 當前全年的每股收益為（$1.70）。威廉·布萊爾還對 Nkarta 2026 財年的每股收益進行了預測，預計為（$1.29）。</p>
<p>Nkarta（納斯達克代碼：NKTX - 獲取免費報告）在 11 月 10 日星期一發布了季度財報。該公司報告的季度每股收益為（$0.29），超出市場普遍預期的（$0.32）$0.03。</p>
<p>其他股票研究分析師也對該公司發佈了研究報告。Weiss Ratings 在 10 月 31 日星期五的研究報告中重新發布了對 Nkarta 股票的 “賣出（d-）” 評級。Needham &amp; Company LLC 在 8 月 13 日星期三的報告中重申了對 Nkarta 的 “買入” 評級，並給出了$10.00 的目標價。華爾街 Zen 在 10 月 25 日星期六的研究報告中將 Nkarta 的評級從 “賣出” 上調至 “持有”。最後，Stifel Nicolaus 在週二的研究報告中將 Nkarta 的目標價從$12.00 下調至$11.00，並對該公司設定了 “買入” 評級。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$13.25。</p>
<p><strong>獲取我們對 Nkarta 的最新股票分析</strong></p>
<h2>Nkarta 股票下跌 2.5%</h2>
<p>納斯達克 NKTX 在星期四開盤價為$1.96。該公司的 50 日簡單移動平均為$2.13，200 日簡單移動平均為$2.01。Nkarta 的 12 個月低點為$1.31，12 個月高點為$3.18。該公司的市值為$139.22 百萬，市盈率為-1.42，貝塔值為 0.86。</p>
<h2>機構投資者對 Nkarta 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Savant Capital LLC 在第二季度購買了價值約$36,000 的 Nkarta 新頭寸。SG Americas Securities LLC 在第三季度將其在 Nkarta 的持倉增加了 35.0%。SG Americas Securities LLC 目前擁有 23,663 股該公司股票，價值$49,000，此前在上個季度又增持了 6,141 股。CWM LLC 在第一季度將其在 Nkarta 的持倉增加了 3,437.3%。CWM LLC 目前擁有 28,157 股該公司股票，價值$52,000，此前在上個季度又增持了 27,361 股。Bailard Inc.在第三季度購買了價值約$61,000 的 Nkarta 新頭寸。最後，Cerity Partners LLC 在第一季度購買了價值約$55,000 的 Nkarta 新頭寸。80.54% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Nkarta</h2>
<p>（獲取免費報告）</p>
<p>Nkarta, Inc.是一家臨牀階段的生物製藥公司，開發和商業化用於癌症和自身免疫疾病治療的自然殺傷細胞療法。該公司的主要產品候選者是 NKX019，一種靶向 CD19 抗原的嵌合抗原受體 - 自然殺傷細胞（CAR NK），目前正在進行針對復發/難治性（r/r）非霍奇金淋巴瘤的 1 期臨牀試驗，以及針對狼瘡性腎炎的治療。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票比 Nkarta 更好</li>
<li>動量投資與長期投資的區別</li>
<li>關於 Holding 的拋售結束的三大理由及新高即將到來</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>隨着沃倫·巴菲特接近退出，伯克希爾積累了創紀錄的現金</li>
<li>現在購買的三隻巨型成長股</li>
<li>稀土股票：並非真正的停火</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Nkarta 嗎？</h2>
<p>在你考慮 Nkarta 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Nkarta 並不在名單上。</p>
<p>雖然 Nkarta 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

NKTX

<p>威廉·布萊爾將 Nkarta 的 2025 財年每股收益（EPS）預估從（$1.38）上調至（$1.36）。市場共識全年每股收益為（$1.70）。2026 財年每股收益預計為（$1.29）。Nkarta 的股票評級為適度買入，市場共識目標價為$13.25。機構投資者持有該股票的 80.54%。Nkarta 開發用於癌症和自身免疫疾病的 CAR NK 療法</p>

<p>Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings per share estimates for Nkarta in a research note issued to investors on Tuesday, November 11th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta's FY2026 earnings at ($1.29) EPS.</p>
<div class="lb-trans"><p>Nkarta, Inc.（納斯達克代碼：NKTX - 免費報告）- 威廉·布萊爾的投資分析師在 11 月 11 日星期二向投資者發佈的研究報告中上調了對 Nkarta 2025 財年每股收益的預期。威廉·布萊爾的分析師 S. Corwin 現在預計該公司 2025 財年每股收益為（$1.36），高於之前預測的（$1.38）。市場普遍預計 Nkarta 當前全年的每股收益為（$1.70）。威廉·布萊爾還對 Nkarta 2026 財年的每股收益進行了預測，預計為（$1.29）。</p>
</div><p>Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03.</p>
<div class="lb-trans"><p>Nkarta（納斯達克代碼：NKTX - 獲取免費報告）在 11 月 10 日星期一發布了季度財報。該公司報告的季度每股收益為（$0.29），超出市場普遍預期的（$0.32）$0.03。</p>
</div><p>Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nkarta in a research note on Friday, October 31st. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Wall Street Zen raised shares of Nkarta from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 25th. Finally, Stifel Nicolaus dropped their price target on shares of Nkarta from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $13.25.</p>
<div class="lb-trans"><p>其他股票研究分析師也對該公司發佈了研究報告。Weiss Ratings 在 10 月 31 日星期五的研究報告中重新發布了對 Nkarta 股票的 “賣出（d-）” 評級。Needham &amp; Company LLC 在 8 月 13 日星期三的報告中重申了對 Nkarta 的 “買入” 評級，並給出了$10.00 的目標價。華爾街 Zen 在 10 月 25 日星期六的研究報告中將 Nkarta 的評級從 “賣出” 上調至 “持有”。最後，Stifel Nicolaus 在週二的研究報告中將 Nkarta 的目標價從$12.00 下調至$11.00，並對該公司設定了 “買入” 評級。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$13.25。</p>
</div><p><strong>Get Our Latest Stock Analysis on Nkarta</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Nkarta 的最新股票分析</strong></p>
</div><h2>Nkarta Stock Down 2.5%</h2>
<div class="lb-trans"><h2>Nkarta 股票下跌 2.5%</h2>
</div><p>NASDAQ NKTX opened at $1.96 on Thursday. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.01. Nkarta has a 12-month low of $1.31 and a 12-month high of $3.18. The firm has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86.</p>
<div class="lb-trans"><p>納斯達克 NKTX 在星期四開盤價為$1.96。該公司的 50 日簡單移動平均為$2.13，200 日簡單移動平均為$2.01。Nkarta 的 12 個月低點為$1.31，12 個月高點為$3.18。該公司的市值為$139.22 百萬，市盈率為-1.42，貝塔值為 0.86。</p>
</div><h2>Institutional Investors Weigh In On Nkarta</h2>
<div class="lb-trans"><h2>機構投資者對 Nkarta 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Savant Capital LLC purchased a new position in shares of Nkarta during the second quarter valued at about $36,000. SG Americas Securities LLC boosted its position in Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company's stock valued at $49,000 after acquiring an additional 6,141 shares in the last quarter. CWM LLC boosted its position in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company's stock valued at $52,000 after acquiring an additional 27,361 shares in the last quarter. Bailard Inc. purchased a new position in shares of Nkarta during the 3rd quarter worth approximately $61,000. Finally, Cerity Partners LLC bought a new position in shares of Nkarta in the 1st quarter worth approximately $55,000. 80.54% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Savant Capital LLC 在第二季度購買了價值約$36,000 的 Nkarta 新頭寸。SG Americas Securities LLC 在第三季度將其在 Nkarta 的持倉增加了 35.0%。SG Americas Securities LLC 目前擁有 23,663 股該公司股票，價值$49,000，此前在上個季度又增持了 6,141 股。CWM LLC 在第一季度將其在 Nkarta 的持倉增加了 3,437.3%。CWM LLC 目前擁有 28,157 股該公司股票，價值$52,000，此前在上個季度又增持了 27,361 股。Bailard Inc.在第三季度購買了價值約$61,000 的 Nkarta 新頭寸。最後，Cerity Partners LLC 在第一季度購買了價值約$55,000 的 Nkarta 新頭寸。80.54% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Nkarta</h2>
<div class="lb-trans"><h2>關於 Nkarta</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.</p>
<div class="lb-trans"><p>Nkarta, Inc.是一家臨牀階段的生物製藥公司，開發和商業化用於癌症和自身免疫疾病治療的自然殺傷細胞療法。該公司的主要產品候選者是 NKX019，一種靶向 CD19 抗原的嵌合抗原受體 - 自然殺傷細胞（CAR NK），目前正在進行針對復發/難治性（r/r）非霍奇金淋巴瘤的 1 期臨牀試驗，以及針對狼瘡性腎炎的治療。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Nkarta</li>
<li>Differences Between Momentum Investing and Long Term Investing</li>
<li>3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming</li>
<li>What is MarketRank™? How to Use it</li>
<li>As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Nkarta 更好</li>
<li>動量投資與長期投資的區別</li>
<li>關於 Holding 的拋售結束的三大理由及新高即將到來</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>隨着沃倫·巴菲特接近退出，伯克希爾積累了創紀錄的現金</li>
<li>現在購買的三隻巨型成長股</li>
<li>稀土股票：並非真正的停火</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nkarta Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Nkarta 嗎？</h2>
</div><p>Before you consider Nkarta, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Nkarta 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Nkarta 並不在名單上。</p>
</div><p>While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Nkarta 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

William Blair 發佈了 Nkarta 的 2025 財年收益預估